Novo Nordisk Strikes a Deal Worth Up to $1.1 Billion to Strengthen Its Cardiovascular Pipeline

Denmark’s Novo Nordisk said on Monday it had agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros ($1.1 billion) to strengthen its cardiovascular pipeline.

The deal is in line with Novo’s aim to expand its focus on diabetes and weight-loss therapies to include cardiovascular disease treatments.

The Danish company has rocketed to become one of the world’s most valuable companies on the back of its hugely popular weight-loss treatment Wegovy.

Read the source article at Yahoo Finance